Longevity tech life science biotech digital health or something else?

I started my longevity investment journey in 2021, brain health for me is the main reason for doing so with Ayuh Ventures, the nucleus to Ageing. While I’m humbled to see 25% of our Longevity Fund I portfolio out of stealth, I’m more excited to see how many more from Fund I make the transition from launch capital to growth capital. My last longevity fund I investment was in a startup working on the intersection of AI & drug discovery in lymphoma, within 90 days of that investment I got my lymphoma diagnosis, and here I am today almost done with my remission journey. A Longevity Fund II centered on patient focus, what can safely be given to patients, and access to healthcare is the reason I’m doing this, after my own health journey, what I saw & experienced during my lymphoma journey led me to this decision: the bottleneck created by Pharma around drug development & drug discovery does not interest me, I’d say the same for med tech & neuro degeneration. A startup that prioritizes pharma & med tech companies to raise from over patient focus isn’t for us, a bold founder who can scale patient focus to challenge the system in this decade is why we do what we do. From digital health to psilocybin to bci & ai tools, there will be a breakout winner for a race to the finish in some genres. It’s quite simple when the incentives are aligned.